OXEIA BIOPHARMACEUTICALS TO PRESENT AT GENESIS 2019 LONDON LIFE SCIENCES CONFERENCE

• Oxeia developing a therapeutic drug to treat concussions.

• Company preparing for launch of Phase II clinical trial.

San Diego, CA, Oxeia Biopharmaceuticals Inc., a clinical stage biotech company developing a drug treatment for concussion and underlying neuro-metabolic dysfunction, today announced that CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference, December 11th, QEII Conference Centre, London. Genesis is hosted by One Nucleus, a leading UK life sciences membership organization.

Dr. Wyand commented, “I am delighted to be a part of this meeting of innovative life sciences and healthcare business leaders and scientists which allows me to share our progress in finding an effective, molecular-driven therapeutic to treat concussions and other acute neurotrauma conditions. In the US alone almost three million cases of traumatic brain injury are seen in hospital emergency rooms and many more go undiagnosed. It’s clearly evident that rest, the primary therapy to date, is not enough and that new clinical solutions are needed.”

Tony Jones, CEO of One Nucleus explained “We are delighted to have Dr. Wyand participating in the session at Genesis. As technology and the molecular understanding of conditions move forward, it is vital we learn how to best harness such advances to address such unmet needs. The Oxeia approach highlights how the industry is putting this new knowledge to effective use and Dr. Wyand will be a great addition to the conference as we debate future directions.”

About Oxeia Biopharmaceuticals http://www.oxeiabiopharma.com/

Headquartered in San Diego, CA, Oxeia Biopharmaceuticals (is a privately held clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. Oxeia’s lead program, OXE-103, is a potent mitochondrial stabilizer that freely crosses the blood brain barrier and activates a well-characterized pathway that directly promotes normal mitochondrial activity to restore brain energy homeostasis. OXE-103 was identified as a therapeutic candidate for concussion through research on the neuro-enteric axis and its effect on brain physiology. The ‘gut-brain’ highway is increasingly a focus of biotechnology research and development in a number of CNS and metabolic conditions. Pre-clinical research with OXE-103 in traumatic brain injury models clearly demonstrated efficacy and confirmed mechanism of activity. Oxeia is now planning to initiate Phase 2 human clinical studies for concussion treatment in 2020.

About One Nucleus and Genesis

Established in 1997, One Nucleus is an award winning not-for-profit life sciences and healthcare membership organisation headquartered in Cambridge, England, Europe’s largest life sciences and healthcare cluster. One Nucleus supports those institutions, companies and individuals in the region and beyond. Building on the evolution of the past 18 years, Genesis 2019 will assemble approximately 750 senior executives and decision-makers from across the life sciences, healthcare and technology fields to present, discuss and demonstrate their collective insights and thought leadership for the sector, themselves and their stakeholders.

For further information, please contact:

Oxeia BioPharmaceuticals
Lindsey McClelland
lmcclelland@oxeiabiopharma.com
+1978 793 0800

Heather Conover
Conover + Gould Strategy Group
hconover@conovergould.com
+1508 789 9273

Ted Agne
Communications Strategy Group Inc.
edagne@comstratgroup.com
+1781 888 0099